Raju Prasad, Ph.D., is the Chief Financial Officer at CRISPR Therapeutics AG, a pioneering biotechnology company focused on developing transformative gene-based medicines using CRISPR/Cas9 gene-editing technology. With more than 25 years of experience in the biotech and pharmaceutical sectors, Dr. Prasad combines deep scientific knowledge with proven financial leadership. He earned his Ph.D. in Biochemistry from the University of California, Berkeley, and an M.B.A. from the University of Chicago Booth School of Business, equipping him to bridge complex scientific innovation with strategic financial management. Before joining CRISPR Therapeutics in 2020, Dr. Prasad served as CFO at bluebird bio, where he led financial operations during a phase of aggressive expansion, including multiple capital raises exceeding $1 billion and preparation for commercial launches in gene therapy. Previously, he was CFO at Relypsa, Inc., overseeing its successful acquisition by Galena Biopharma (now sold to Mallinckrodt), and held senior finance roles at Genentech and Gilead Sciences, contributing to blockbuster product launches and global financial strategies. In his current role at CRISPR Therapeutics, Dr. Prasad oversees all financial functions, including capital markets activities, investor relations, treasury, and risk management, supporting the company's robust pipeline of investigational therapies for hemoglobinopathies, oncology, and regenerative medicine. His leadership has been instrumental in securing strategic partnerships, such as with Vertex Pharmaceuticals, and advancing toward key clinical and regulatory milestones, positioning CRISPR Therapeutics for sustained growth in the genomic medicine landscape.